お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
963079

神経痛治療の世界市場:治療別(薬物ベース、外科)、最終用途別(病院・診療所、外来手術センター)、地域別の市場規模、シェアおよび動向分析、セグメント別予測(2020年~2027年)

Neuralgia Treatment Market Size, Share & Trends Analysis Report By Treatment (Drug Based, Surgery), By End Use (Hospital & Clinics, Ambulatory Surgery Centers), By Region, And Segment Forecasts, 2020 - 2027

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 114 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.53円
神経痛治療の世界市場:治療別(薬物ベース、外科)、最終用途別(病院・診療所、外来手術センター)、地域別の市場規模、シェアおよび動向分析、セグメント別予測(2020年~2027年)
出版日: 2020年09月07日
発行: Grand View Research, Inc.
ページ情報: 英文 114 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の神経痛治療の市場規模は、予測期間中にCAGR 6.0%で拡大し、2027年までに28億米ドルに達すると予想されています。高齢者人口の増加、三叉神経痛の発生率の増加、および糖尿病の有病率の上昇が、市場成長を促進する主要な要因となっています。神経痛は、神経の損傷または炎症によるヒリヒリし、突き刺すような、激しい痛みです。

神経の慢性的な痛みは、感染、糖尿病、老化、多発性硬化症、または特定の神経を保護するミエリン鞘を損傷する同様の障害などのさまざまな要因によって発生する可能性があります。三叉神経を圧迫する腫瘍も障害を引き起こす可能性があります。三叉神経の慢性疼痛の有病率は、高齢化人口とともに増加しています。 WHOによると、高齢者人口は2015年の9億人から2050年には20億人に増加すると予測されています。高齢者は、糖尿病や三叉神経痛などの多くの病気にかかりやすい傾向があります。

当レポートでは、世界の神経痛治療市場について調査分析し、市場および業界の見通し、セグメント別・地域別の見通しのほか、競合情勢について、体系的な情報を提供しています。

目次

第1章 調査範囲

  • 市場細分化と範囲
  • 地域の範囲
  • 推計および予測のタイムライン

第2章 調査方法

第3章 目的

  • 目的-1
  • 目的-2
  • 目的-3
  • 目的-4

第4章 エグゼクティブサマリー

第5章 業界の見通し

  • 浸透と成長の見通しのマッピング
  • 規制の枠組み
  • 市場力学
    • 市場の成長要因分析
    • 市場抑制要因分析
  • 神経痛治療市場分析ツール
    • PEST別SWOT分析
    • ポーターのファイブフォース分析

第6章 神経痛治療市場:治療別セグメント分析、2016年~2027年(百万米ドル)

  • 定義と範囲
  • 治療別市場シェア分析、2019年および2027年
  • 神経痛治療市場、治療別、2016年~2027年
  • 市場規模の予測・動向分析

第7章 神経痛治療市場:最終用途別セグメント分析、2016年~2027年(百万米ドル)

  • 定義と範囲
  • 最終用途別市場シェア分析、2019年および2027年
  • 神経痛治療市場、最終用途別、2016年~2027年
  • 市場規模の予測・動向分析
    • 病院・クリニック
    • 外来手術センター
    • その他

第8章 神経痛治療市場:地域市場分析、治療別、および最終用途別、2016年~2027年(百万米ドル)

  • 定義と範囲
  • 地域市場シェア分析、2019年および2027年
  • 地域市場のスナップショット
  • 市場規模の予測・動向分析
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中南米
    • 中東・アフリカ

第9章 神経痛治療市場:競合分析

  • 企業プロファイル
    • GlaxoSmithKline PLC
    • Pfizer Inc.
    • Novartis AG
    • Biogen
    • Cadila Healthcare Limited
    • Lundbeck Pharmaceuticals LLC
図表

List of Tables

  • Table 1 Primary interview details: North America
  • Table 2 Primary interview details: Europe
  • Table 3 Primary interview details: APAC
  • Table 4 Primary interview details: Latin America
  • Table 5 Primary interview details: MEA
  • Table 6 List of secondary sources
  • Table 7 List of abbreviation
  • Table 8 North America neuralgia treatment market, by country, 2016 - 2027 (USD Million)
  • Table 9 North America neuralgia treatment market, by treatment, 2016 - 2027 (USD Million)
  • Table 10 North America neuralgia treatment market, by end use, 2016 - 2027 (USD Million)
  • Table 11 The U.S. neuralgia treatment market, by treatment, 2016 - 2027 (USD Million)
  • Table 12 The U.S. neuralgia treatment market, by end use, 2016 - 2027 (USD Million)
  • Table 13 Canada neuralgia treatment market, by treatment, 2016 - 2027 (USD Million)
  • Table 14 Canada neuralgia treatment market, by end use, 2016 - 2027 (USD Million)
  • Table 15 Europe neuralgia treatment market, by country, 2016 - 2027 (USD Million)
  • Table 16 Europe neuralgia treatment market, by treatment, 2016 - 2027 (USD Million)
  • Table 17 Europe neuralgia treatment market, by end use, 2016 - 2027 (USD Million)
  • Table 18 The U.K. neuralgia treatment market, by treatment, 2016 - 2027 (USD Million)
  • Table 19 The U.K. neuralgia treatment market, by end use, 2016 - 2027 (USD Million)
  • Table 20 Germany neuralgia treatment market, by treatment, 2016 - 2027 (USD Million)
  • Table 21 Germany neuralgia treatment market, by end use, 2016 - 2027 (USD Million)
  • Table 22 Asia Pacific neuralgia treatment market, by country, 2016 - 2027 (USD Million)
  • Table 23 Asia Pacific neuralgia treatment market, by treatment, 2016 - 2027 (USD Million)
  • Table 24 Asia Pacific neuralgia treatment market, by end use, 2016 - 2027 (USD Million)
  • Table 25 Japan neuralgia treatment market, by treatment, 2016 - 2027 (USD Million)
  • Table 26 Japan neuralgia treatment market, by end use, 2016 - 2027 (USD Million)
  • Table 27 China neuralgia treatment market, by treatment, 2016 - 2027 (USD Million)
  • Table 28 China neuralgia treatment market, by end use, 2016 - 2027 (USD Million)
  • Table 29 Latin America neuralgia treatment market, by country, 2016 - 2027 (USD Million)
  • Table 30 Latin America neuralgia treatment market, by treatment, 2016 - 2027 (USD Million)
  • Table 31 Latin America neuralgia treatment market, by end use, 2016 - 2027 (USD Million)
  • Table 32 Brazil neuralgia treatment market, by treatment, 2016 - 2027 (USD Million)
  • Table 33 Brazil neuralgia treatment market, by end use, 2016 - 2027 (USD Million)
  • Table 34 Mexico neuralgia treatment market, by treatment, 2016 - 2027 (USD Million)
  • Table 35 Mexico neuralgia treatment market, by end use, 2016 - 2027 (USD Million)
  • Table 36 Middle East & Africa neuralgia treatment market, by country, 2016 - 2027 (USD Million)
  • Table 37 Middle East & Africa neuralgia treatment market, by treatment, 2016 - 2027 (USD Million)
  • Table 38 Middle East & Africa neuralgia treatment market, by end use, 2016 - 2027 (USD Million)
  • Table 39 South Africa neuralgia treatment market, by treatment, 2016 - 2027 (USD Million)
  • Table 40 South Africa neuralgia treatment market, by end use, 2016 - 2027 (USD Million)
  • Table 41 Saudi Arabia neuralgia treatment market, by treatment, 2016 - 2027 (USD Million)
  • Table 42 Saudi Arabia neuralgia treatment market, by end use, 2016 - 2027 (USD Million)

List of Figures

  • Fig. 1 Neuralgia Treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market summary (2019)
  • Fig. 10 Penetration & growth prospect mapping
  • Fig. 11 Market driver relevance analysis (Current & future impact)
  • Fig. 12 Market restraint relevance analysis (Current & future impact)
  • Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Neuralgia treatment market: Treatment movement analysis
  • Fig. 16 Neuralgia treatment market treatment outlook: Key takeaways
  • Fig. 17 Drug based market, 2016 - 2027 (USD Million)
  • Fig. 18 Anticonvulsant medicines market, 2016 - 2027 (USD Million)
  • Fig. 19 Tricyclic antidepressants market, 2016 - 2027 (USD Million)
  • Fig. 20 Surgery market, 2016 - 2027 (USD Million)
  • Fig. 21 Radiofrequency thermal lesioning market, 2016 - 2027 (USD Million)
  • Fig. 22 Stereotactic Radiosurgery market, 2016 - 2027 (USD Million)
  • Fig. 22 Microvascular decompression market, 2016 - 2027 (USD Million)
  • Fig. 23 Others market, 2016 - 2027 (USD Million)
  • Fig. 24 Neuralgia treatment market: End Use movement analysis
  • Fig. 25 Neuralgia treatment market end use outlook: Key takeaways
  • Fig. 26 Hospitals& clinics market, 2016 - 2027 (USD Million)
  • Fig. 27 Ambulatory surgery center market, 2016 - 2027 (USD Million)
  • Fig. 28 Others market, 2016 - 2027 (USD Million)
  • Fig. 29 Regional Outlook, 2019 & 2027
  • Fig. 30 Regional market place: Key takeaways
  • Fig. 31 North America neuralgia treatment market, 2016 - 2027 (USD Million)
  • Fig. 32 The U.S. neuralgia treatment market, 2016 - 2027 (USD Million)
  • Fig. 33 Canada neuralgia treatment market, 2016 - 2027 (USD Million)
  • Fig. 34 Europe neuralgia treatment market, 2016 - 2027 (USD Million)
  • Fig. 35 The U.K. neuralgia treatment market, 2016 - 2027 (USD Million)
  • Fig. 36 Germany neuralgia treatment market, 2016 - 2027 (USD Million)
  • Fig. 37 Asia Pacific neuralgia treatment market, 2016 - 2027 (USD Million)
  • Fig. 38 Japan neuralgia treatment market, 2016 - 2027 (USD Million)
  • Fig. 39 China neuralgia treatment market, 2016 - 2027 (USD Million)
  • Fig. 40 Latin America neuralgia treatment market, 2016 - 2027 (USD Million)
  • Fig. 41 Brazil neuralgia treatment market, 2016 - 2027 (USD Million)
  • Fig. 42 Mexico neuralgia treatment market, 2016 - 2027 (USD Million)
  • Fig. 43 Middle East & Africa neuralgia treatment market, 2016 - 2027 (USD Million)
  • Fig. 44 South Africa neuralgia treatment market, 2016 - 2027 (USD Million)
  • Fig. 45 Saudi Arabia neuralgia treatment market, 2016 - 2027 (USD Million)
目次
Product Code: GVR-4-68039-022-8

Neuralgia Treatment Market Growth & Trends

The global neuralgia treatment market size is expected to reach USD 2.8 billion by 2027, expanding at a CAGR of 6.0%, according to a new report by Grand View Research, Inc. The rising geriatric population, increasing incidence of trigeminal neuralgia, and the growing prevalence of diabetes are the key factors driving the market. Neuralgia is a burning, stabbing, and severe pain due to a damaged or irritated nerve.

The chronic pain in the nerves can occur due to various factors such as infection, diabetes, aging, multiple sclerosis, or any similar disorders that damage the myelin sheath protecting certain nerves. Tumor compressing the trigeminal nerve can also cause the disorder. The prevalence of chronic pain in the trigeminal nerve increases with the aging population. According to the estimates published by the WHO, the geriatric population is anticipated to rise from 900.0 million in 2015 to 2.0 billion in 2050. The geriatric population is prone to many diseases such as diabetes and trigeminal neuralgia.

As per the American Association of Neuromuscular and Electrodiagnostic Medicine, the disorder usually affects the population aged 50 years or older. It also reported that women are more prone to trigeminal neuralgia than men. As per the study, The Patient's Journey Through Trigeminal Neuralgia published by the International Association for The Study of Pain (IASP), the incidence rate of the disorder in the general population is 3.4 to 5.9 per 100,000 population. It also reported that the incidence rate is comparatively higher in the geriatric population. Such factors are expected to boost market growth over the forecast period. Stereotactic radiosurgery and microvascular decompression are the two most common procedures being adopted to treat the disorder.

Neuralgia Treatment Market Report Highlights

On the basis of treatment, the surgery segment held the largest market share in 2019 owing to rising awareness regarding various treatment options and the high cost of surgeries

The surgery segment has been further sub-segmented into Radiofrequency Thermal Lesioning, Stereotactic Radiosurgery, Microvascular Decompression, and others

The ambulatory surgery center segment is anticipated to witness the fastest growth over the forecast period owing to the rising demand for a reduced hospital stay

In North America, the market held the largest revenue share in 2019 owing to the presence of key players in the region.

Table of Contents

Chapter 1 Report Scope

  • 1.1 Market Segmentation and Scope
  • 1.2 Regional Scope
  • 1.3 Estimates and Forecast Timeline

Chapter 2 Research Methodology

  • 2.1 Research Methodology
    • 2.1.1 Information procurement
  • 2.2 Information or Data Analysis
  • 2.3 Market Formulation & Validation
  • 2.4 Region Wise Market Calculation
    • 2.4.1 Region Wise Market: Base Estimates
    • 2.4.2 Global Market: CAGR Calculation
  • 2.5 Region Based Segment Share Calculation
  • 2.6 Model Details
    • 2.6.1 Commodity Flow Analysis (Model 1)
    • 2.6.2 Volume price analysis (Model 2)
  • 2.7 List of Secondary Sources

Chapter 3 Objectives

  • 3.1 Objective - 1
  • 3.2 Objective - 2
  • 3.3 Objective - 3
  • 3.4 Objective - 4

Chapter 4 Executive Summary

  • 4.1 Market Outlook
  • 4.2 Segment Outlook
  • 4.3 Competitive Insights
  • 4.4 Market Snapshot

Chapter 5 Industry Outlook

  • 5.1 Penetration & Growth Prospect Mapping
  • 5.2 Regulatory Framework
  • 5.3 Market Dynamics
    • 5.3.1 Market driver analysis
      • 5.3.1.1 Rising prevalence of trigeminal neuralgia
      • 5.3.1.2 Increase in geriatric population across the globe
      • 5.3.1.3 Increase in prevalence of diabetes
    • 5.3.2 Market restraint analysis
      • 5.3.2.1 High cost of surgery
  • 5.4 Neuralgia Treatment Market Analysis Tools
    • 5.4.1 SWOT Analysis, by PEST
    • 5.4.2 Porter's five forces analysis

Chapter 6 Neuralgia Treatment Market: Segment Analysis, By Treatment, 2016 - 2027 (USD Million)

  • 6.1 Definitions & Scope
  • 6.2 Treatment Market Share Analysis, 2019 & 2027
  • 6.3 Neuralgia Treatment Market, by Treatment, 2016 to 2027
  • 6.4 Market Size Forecasts and Trend Analysis
      • 6.4.1Drug Based
      • 6.4.1.1 Drug based market, 2016 - 2027 (USD Million)
      • 6.4.1.2 Anticonvulsant Medicines
      • 6.4.1.2.1 Anticonvulsant medicines market, 2016 - 2027 (USD Million)
      • 6.4.1.3 Tricyclic antidepressants
      • 6.4.1.3.1 Tricyclic antidepressantsmarket, 2016 - 2027 (USD Million)
      • 6.4.2Surgery
      • 6.4.2.1 Surgery market, 2016 - 2027 (USD Million)
      • 6.4.2.2 Radiofrequency Thermal Lesioning
      • 6.4.2.2.1 Radiofrequency thermal lesioning market, 2016 - 2027 (USD Million)
      • 6.4.2.3 Stereotactic Radiosurgery
      • 6.4.2.3.1 Stereotactic radiosurgerymarket, 2016 - 2027 (USD Million)
      • 6.4.2.4 Microvascular Decompression
      • 6.4.2.4.1 Microvascular decompressionmarket, 2016 - 2027 (USD Million)
      • 6.4.2.5 Others
      • 6.4.2.5.1 Others market, 2016 - 2027 (USD Million)

Chapter 7 Neuralgia Treatment Market: Segment Analysis, By End Use 2016 - 2027 (USD Million)

  • 7.1 Definitions & Scope
  • 7.2 End Use Market Share Analysis, 2019 & 2027
  • 7.3 Neuralgia Treatment Market, by End Use, 2016 to 2027
  • 7.4 Market Size Forecasts and Trend Analysis
    • 7.4.1 Hospitals & Clinics
      • 7.4.1.1 Hospitals & clinics market, 2016 - 2027 (USD Million)
    • 7.4.2 Ambulatory Surgery Center
      • 7.4.2.1 Ambulatory surgery centermarket, 2016 - 2027 (USD Million)
    • 7.4.3 Others
      • 7.4.3.1 Others market, 2016 - 2027 (USD Million)

Chapter 8 Neuralgia Treatment Market: Regional Market Analysis, By Treatment, and End Use, 2016 - 2027 (USD Million)

  • 8.1 Definitions & Scope
  • 8.2 Regional Market Share Analysis, 2019 & 2027
  • 8.3 Regional Market Snapshot
  • 8.4 Market Size Forecasts & Trend Analysis
    • 8.4.1 North America
      • 8.4.1.1 North America neuralgia treatment market, 2016 - 2027 (USD Million)
      • 8.4.1.2 The U.S.
      • 8.4.1.2.1 The U.S. neuralgia treatment market, 2016 - 2027 (USD Million)
      • 8.4.1.3 Canada
      • 8.4.1.3.1 Canada neuralgia treatment market, 2016 - 2027 (USD Million)
    • 8.4.2 Europe
      • 8.4.2.1 Europe neuralgia treatment market, 2016 - 2027 (USD Million)
      • 8.4.2.2 The U.K.
      • 8.4.2.2.1 The U.K. neuralgia treatment market, 2016 - 2027 (USD Million)
      • 8.4.2.3 Germany
      • 8.4.2.3.1 Germany neuralgia treatment market, 2016 - 2027 (USD Million)
    • 8.4.3 Asia Pacific
      • 8.4.3.1 Asia Pacific neuralgia treatment market, 2016 - 2027 (USD Million)
      • 8.4.3.2 Japan
      • 8.4.3.2.1 Japan neuralgia treatment market, 2016 - 2027 (USD Million)
      • 8.4.3.3 China
      • 8.4.3.3.1 China neuralgia treatment market, 2016 - 2027 (USD Million)
    • 8.4.4 Latin America
      • 8.4.4.1 Latin America neuralgia treatment market, 2016 - 2027 (USD Million)
      • 8.4.4.2 Brazil
      • 8.4.4.2.1 Brazil neuralgia treatment market, 2016 - 2027 (USD Million)
      • 8.4.4.3 Mexico
      • 8.4.4.3.1 Mexico neuralgia treatment market, 2016 - 2027 (USD Million)
    • 8.4.5 Middle East & Africa
      • 8.4.5.1 Middle East & Africa neuralgia treatmentmarket, 2016 - 2027 (USD Million)
      • 8.4.5.2 South Africa
      • 8.4.5.2.1 South Africa neuralgia treatment market, 2016 - 2027 (USD Million)
      • 8.4.5.3 Saudi Arabia
      • 8.4.5.3.1 Saudi Arabia neuralgia treatment market, 2016 - 2027 (USD Million)

Chapter 9 Neuralgia Treatment Market: Competitive Analysis

  • 9.1 Company Profiles
    • 9.1.1 GlaxoSmithKline PLC
      • 9.1.1.1 Company overview
      • 9.1.1.2 Financial performance
      • 9.1.1.3 Product benchmarking
      • 9.1.1.4 Strategic initiatives
    • 9.1.2 Pfizer Inc.
      • 9.1.2.1 Company overview
      • 9.1.2.2 Financial performance
      • 9.1.2.3 Product benchmarking
      • 9.1.2.4 Strategic initiatives
    • 9.1.3 Novartis AG
      • 9.1.3.1 Company overview
      • 9.1.3.2 Financial performance
      • 9.1.3.3 Product benchmarking
      • 9.1.1.4 Strategic initiatives
    • 9.1.4 Biogen
      • 9.1.4.1 Company overview
      • 9.1.4.2 Financial performance
      • 9.1.4.3 Product benchmarking
      • 9.1.4.4 Strategic initiatives
    • 9.1.5 Cadila Healthcare Limited
      • 9.1.5.1 Company overview
      • 9.1.5.2 Financial performance
      • 9.1.5.3 Product benchmarking
      • 9.1.5.4 Strategic initiatives
    • 9.1.6 Lundbeck Pharmaceuticals LLC
      • 9.1.6.1 Company overview
      • 9.1.6.2 Financial performance
      • 9.1.6.3 Product benchmarking
      • 9.1.6.4 Strategic initiatives
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.